FilingReader Intelligence
Aarti Drugs reports 6% revenue growth in Q1
July 25, 2025 at 05:39 PM UTC•By FilingReader AI
Aarti Drugs Limited reported Q1 FY26 revenues of INR591 crores, up 6% year-on-year, with gross profit margins improving to 36.8%. EBITDA increased 12% to INR74 crores.
The formulation business grew 14% to INR80 crores, while API business expanded 5%. The company plans INR150-200 crores capex for FY26.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:AARTIDRUGS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Aarti Drugs publishes news
Free account required • Unsubscribe anytime